Anti-IgE – emerging opportunities for Omalizumab

Babu, K. Suresh; Polosa, Riccardo; Morjaria, Jaymin B.

doi:10.1517/14712598.2013.782391

Cited by 52 publications

(50 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bilastine shows the lowest risk of interactions with other drugs as compared with different antihistamines, which is associated with its pharmacokinetic and pharmacodynamic profile [46][47][48][49][50][51][52][53][54][55][56][57][58].…”

Section: Use Of Antihistamines In Treatment Of Viral Infections Of Thmentioning

confidence: 99%

The role and choice criteria of antihistamines in allergy management – Expert opinion

Kuna

Jurkiewicz

Czarnecka‐Operacz

et al. 2017

Alergologia Polska - Polish Journal of Allergology

View full text Add to dashboard Cite

A b s t r a c tAllergic diseases are the most common chronic conditions lasting throughout the patient's life. They not only cause significant deterioration in the quality of life of patients but also lead to significant absenteeism and reduced productivity, resulting in very high costs for society. Effective and safe treatment of allergic diseases is therefore one of the main challenges for public health and should be carried out by all the specialists in family medicine, internists and paediatricians in collaboration with allergists, otorhinolaryngologists and dermatologists. Antihistamines are most commonly used in the treatment of allergies. Several dozen drugs are available on the pharmaceutical market, and their generic forms are advertised widely as very effective drugs for the treatment of allergic diseases. What is the truth? What are the data from clinical trials and observational studies? Are all drugs equally effective and safe for the patient? According to a panel of experts representing various fields of medicine, inappropriate treatment of allergies can be very risky for patients, and seemingly equally acting medications may differ greatly. Therefore, a panel of experts gathered the latest data from the entire scientific literature and analysed the latest standards and recommendations prepared by scientific societies. This paper provides a summary of these studies and highlights the importance for the patient of the proper choice of drug to treat his allergies.Key words: antihistamines, bilastin, allergic rhinitis, urticaria, allergy. Which antihistamines should be chosen according to current standards and recommendations?In the last few decades the incidence of allergic diseases has grown to epidemic status. According to the current data, more than 600 million people suffer from allergic rhinitis worldwide, approximately 25% of them in Europe. In the ECAP trial (Epidemiology of Allergic Diseases in Poland) as many as 30% of respondents reported allergic rhinitis, less than 7% mentioned urticaria, but over 40% of patients had positive skin tests with common inhaled allergens (e.g. plant pollen, dust mites, mould and animal hair). Despite this huge number of patients, these data are frequently underestimated, since allergic diseases are generally believed to be trivial and non-hazardous. However, it has already been proven that allergic rhinitis, asthma and urticaria are associated with a significant socioeconomic burden all over the world -regardless of region, development level and financial status. The total cost of allergic diseases brings both reduced quality of life and also direct costs of drugs and health services as well as indirect social costs such as the absence from work; it also decreases productivity and concentration and generates learning disorders and

show abstract

Section: Use Of Antihistamines In Treatment Of Viral Infections Of Thmentioning

confidence: 99%

The role and choice criteria of antihistamines in allergy management – Expert opinion

Kuna

Jurkiewicz

Czarnecka‐Operacz

et al. 2017

Alergologia Polska - Polish Journal of Allergology

View full text Add to dashboard Cite

show abstract

“…[160][161][162] Xolair® omalizumab has been investigated in various other conditions including perennial and seasonal allergic rhinitis, idiopathic anaphylaxis, mastocytosis, peanut allergy, latex allergy, atopic dermatitis, chronic urticaria, eosinophilic gastroenteritis, and nasal polyposis, with increasing success (see ref. 163 for a review). In this context, the analytical assessment of allergy desensitization subsequent to immunotherapy may promote BAT as an eligible tool to highlight allergy in individuals undergoing treatment.…”

Section: Immunotherapy With Monoclonal Anti-iges and Batmentioning

confidence: 99%

“…174 This recombinant anti-IgE moAb has been investigated in several other allergic conditions, and has become a promising immunotherapeutic for several forms of allergy. 163,175 The use of BAT in omalizumab therapy does not seem to account on a significant amount of practitioners, except for very few reports.…”

Section: Immunotherapy With Monoclonal Anti-iges and Batmentioning

confidence: 99%

Immunotherapy in allergy and cellular tests

Chirumbolo

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Accumulating evidence has shown that IgE, by binding to FcεRI on mast cells without FcεRI cross-linking, can promote the proliferation and survival of mast cells and thus maintain and expand the pool of mast cells. IgE and FcεRI engagement can also decrease the release threshold of mast cells and increase their sensitivity to various stimuli through either FcεRI or other receptors for the degranulation process [11,12]. The development of Omalizumab therapy over the past 20 years provides an interesting example of the emergence of a conceptually new, biotechnology-produced pharmaceutical [13][14][15][16][17][18].…”

Section: Omalizumabmentioning

confidence: 99%

“…In addition to skin blisters, patients with BP often experience pruritus and erythematous urticaria-like skin lesions. CD200 (OX-2) is a novel immune-effective molecule, both cell membrane-bound and also existing in a soluble form in serum (sCD200, sOX-2), which acts both as a pro-inflammatory through its receptor [11,14,47]. In our previous study, we reported a patient who had a pru ritic bullous pemphigoid and very high levels of total IgE (5000 kU/L) who was refractory to the aggressive immunosuppressive regimens for bullous pemphigoid but responded rapidly to systemic anti-IgE.…”

Section: Omalizumab Effects On Pru Ritic Bullous Pemphigoidmentioning

confidence: 99%

ANTI-Ige: An Overview

Yalçın¹

2014

Glob J Allergy

View full text Add to dashboard Cite

Asthma is common chronic inflammatory disease of the airways characterised by variable and attacks of cough and breathlesness, usually precipitated by an enviromental trigger (air pollution, smoke, etc). The prevalence and severity for allergic asthma have increased markedly in the last several decades. Dysregulated expression patterns of pro-and anti inflammatory mechanisms are thought to be responsible for the development of chronic inflammation. The risk of developing asthma has a strong genetic component, with estimated heritability ranging from 35 to 85%. The mechanism of action of Omalizumab in the treatment of asthma is believed to be multifactorial.

show abstract

Anti-IgE – emerging opportunities for Omalizumab

Abstract: We feel that the future of Omalizumab would include a more diverse range of clinical conditions, and future trials should not only look into the clinical usefulness but also the economic impact of using this interesting molecule.

Cited by 52 publications

References 103 publications

The role and choice criteria of antihistamines in allergy management – Expert opinion

The role and choice criteria of antihistamines in allergy management – Expert opinion

Immunotherapy in allergy and cellular tests

ANTI-Ige: An Overview

Contact Info

Product

Resources

About